Semaglutide induced Pancreatitis

Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is widely used for managing type 2 diabetes due to its efficacy in enhancing insulin secretion and facilitating weight loss. Despite its benefits, concerns have arisen regarding the potential risk of acute pancreatitis (AP) associated with GLP-1 RA use. Although the Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) trial did not show a significant increase in AP risk with semaglutide, some studies indicate a possible link between GLP-1 RAs and pancreatic inflammation. This case is about a patient with AP who was recently started on semaglutide. The increasing use of GLP-1 RAs necessitates awareness of their potential to cause pancreatic complications, underscoring the need for ongoing research and clinical vigilance to better understand and manage this risk.